Cargando…
Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
The COVID-19 pandemic has led to health, social and economic consequences for public health systems. As a result, the development of safe and effective vaccines, in order to contain the infection quickly became a priority. The first vaccine approved by the Italian Agency for Drugs Authorization (AIF...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472926/ https://www.ncbi.nlm.nih.gov/pubmed/34579184 http://dx.doi.org/10.3390/vaccines9090947 |
_version_ | 1784574859699814400 |
---|---|
author | Coppeta, Luca Somma, Giuseppina Ferrari, Cristiana Mazza, Andrea Rizza, Stefano Trabucco Aurilio, Marco Perrone, Stefano Magrini, Andrea Pietroiusti, Antonio |
author_facet | Coppeta, Luca Somma, Giuseppina Ferrari, Cristiana Mazza, Andrea Rizza, Stefano Trabucco Aurilio, Marco Perrone, Stefano Magrini, Andrea Pietroiusti, Antonio |
author_sort | Coppeta, Luca |
collection | PubMed |
description | The COVID-19 pandemic has led to health, social and economic consequences for public health systems. As a result, the development of safe and effective vaccines, in order to contain the infection quickly became a priority. The first vaccine approved by the Italian Agency for Drugs Authorization (AIFA) was the BNT162b2 mRNA vaccine, developed by BioNTech and Pfizer (Comirnaty). Comirnaty contains a molecule called messenger RNA (mRNA), which is a nucleoside-modified RNA that encodes the SARS-CoV-2 spike glycoprotein. Even if data from phase I suggest that vaccine induced antibodies can persist for up to six months following the second shot of BNT vaccine, data regarding the real duration of immunological protection are lacking. In this study, we aimed to evaluate the duration of serological protection by detecting the presence of anti-S-RBD (receptor-binding domain) antibodies for SARS-CoV-2 among a large group of healthcare workers (HCWs) three months after vaccination. 99% of HCWs had a detectable titre of anti-S SARS-CoV-2 antibodies 90 days after the second vaccine shot. Elderly operators showed significantly lower levels of protective antibodies when compared to the younger ones, thus they could become unprotected earlier than other operators. |
format | Online Article Text |
id | pubmed-8472926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84729262021-09-28 Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Coppeta, Luca Somma, Giuseppina Ferrari, Cristiana Mazza, Andrea Rizza, Stefano Trabucco Aurilio, Marco Perrone, Stefano Magrini, Andrea Pietroiusti, Antonio Vaccines (Basel) Article The COVID-19 pandemic has led to health, social and economic consequences for public health systems. As a result, the development of safe and effective vaccines, in order to contain the infection quickly became a priority. The first vaccine approved by the Italian Agency for Drugs Authorization (AIFA) was the BNT162b2 mRNA vaccine, developed by BioNTech and Pfizer (Comirnaty). Comirnaty contains a molecule called messenger RNA (mRNA), which is a nucleoside-modified RNA that encodes the SARS-CoV-2 spike glycoprotein. Even if data from phase I suggest that vaccine induced antibodies can persist for up to six months following the second shot of BNT vaccine, data regarding the real duration of immunological protection are lacking. In this study, we aimed to evaluate the duration of serological protection by detecting the presence of anti-S-RBD (receptor-binding domain) antibodies for SARS-CoV-2 among a large group of healthcare workers (HCWs) three months after vaccination. 99% of HCWs had a detectable titre of anti-S SARS-CoV-2 antibodies 90 days after the second vaccine shot. Elderly operators showed significantly lower levels of protective antibodies when compared to the younger ones, thus they could become unprotected earlier than other operators. MDPI 2021-08-25 /pmc/articles/PMC8472926/ /pubmed/34579184 http://dx.doi.org/10.3390/vaccines9090947 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Coppeta, Luca Somma, Giuseppina Ferrari, Cristiana Mazza, Andrea Rizza, Stefano Trabucco Aurilio, Marco Perrone, Stefano Magrini, Andrea Pietroiusti, Antonio Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 |
title | Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 |
title_full | Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 |
title_fullStr | Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 |
title_full_unstemmed | Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 |
title_short | Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 |
title_sort | persistence of anti-s titre among healthcare workers vaccinated with bnt162b2 mrna covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472926/ https://www.ncbi.nlm.nih.gov/pubmed/34579184 http://dx.doi.org/10.3390/vaccines9090947 |
work_keys_str_mv | AT coppetaluca persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19 AT sommagiuseppina persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19 AT ferraricristiana persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19 AT mazzaandrea persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19 AT rizzastefano persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19 AT trabuccoauriliomarco persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19 AT perronestefano persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19 AT magriniandrea persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19 AT pietroiustiantonio persistenceofantistitreamonghealthcareworkersvaccinatedwithbnt162b2mrnacovid19 |